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What is Pediatric Neuroblastoma?
• One of the most common cancers seen in infants and
children
• Has one of the highest mortality rates when compared
to other forms of pediatric cancers
• Begins in the nerve cells
• Most commonly in the abdomen and the adrenal
glands
• Can be present in the neck or spinal cord
• Has a high chance of metastasis
• Rapidly spreads to other areas of the body,
commonly throughout the nervous system
• Each case of pediatric neuroblastoma develops in
different ways, and symptoms vary for each patient
• Many experience pain and life-long residual issues,
along with many neurological issues

• In each of the following studies, participants were analyzed to

Radiation Therapy
• Leads to increased chance of survival and elimination of the tumor.
• This is due to the radiation therapy killing cancer cells, as well as slowing
their growth by damaging their DNA (Robbins et al., 2010).
• Radiation therapy takes a long time in order to see results, so this treatment
option needs to begin early on, to then be complemented with other
treatment options in the future (Robbins et al., 2010).
Surgical treatment
• Patients who receive surgical treatment at later stages were equally as likely
to suffer mortality than patients who had no surgical treatment done (Simon
et al., 2013).
• Patients who received surgical treatment early, while tumors were small, had
a much higher overall survival rate (Strotheret al, 2012).
• This was because patients in late stages of neuroblastoma often had the
cancer spread through most of their brain and body (Englum et al., 2015).
• Surgical treatment as a sole and only treatment option is only viable if there
is an early detection of neuroblastoma; in late stages of neuroblastoma
surgical treatment should be avoided (Strotheret et al., 2012).
Medication
• Dinutuximab and nanomedicine were both proven as effective forms of
complementary treatment for neuroblastoma.
• Dinutuximab has been a top tier choose of medicine for high-risk
neuroblastoma patients, this medication binds to cell surface GD2 and causes
the death of the targeted cells (McGinty et al., 2017).
• Nanotechnology can provide rapid and sensitive detection of cancer-related
molecules, enabling scientists to detect molecular changes even when they
occur only in a small percentage of cells (Alferiev et al., 2015).
• These treatment options, should not be used as sole treatment options to treat
neuroblastoma in pediatric patients.
Chemotherapy
• Chemotherapy treatment is an exceptional treatment option because it
prevents cancer cells from growing, dividing, and making more cells
(Coburn et al., 2016).
• Chemotherapy uses drugs to destroy cancer cells, but in the process many
adverse effects occur, and an overall worse quality of life is reported (Habib
et al., 2012).
• This worse quality of life is often why chemotherapy treatment is started
when neuroblastoma aggressively spreads throughout the body (Ladenstein et
al., 2017).
• Should be used with radiation therapy for best results are seen (Coburn et al.,
2016).
• Cycles of high chemotherapy with radiation therapy for 2 to 6 week (Boburn
et al., 2016).
• Four to eight cycles needed in order to completely eradicate the spread of
neuroblastoma in pediatric patients (Boburn et al., 2016).

• Radiation should almost always be used as a treatment option
(Robbins et al., 2010).
• Surgical treatment should be used for early to mid-stages of
detection and diagnosis of neuroblastoma (Stother, 2012).
• Surgical treatment is often paired with other treatment options
in later stages (Stother et al, 2012).
• Medication have been proven to be effective complementary
treatment options to chemotherapy, radiation therapy, and
surgical treatment (Alferiev et al., 2015).
• These treatment options do not have sufficient data behind
them to be used as sole treatment options for pediatric
patients with neuroblastoma (McGinty et al., 2017).
• Chemotherapy should be saved for late stages, when cancer
begins to aggressively spread though out the body (Ladenstein
et al., 2017).

determine the effects of their treatment option (i.e., radiation,
chemotherapy, surgery, medication) to determine both longterm effects and short-term effects directly related to the
progression of the tumor.
• All of the mentioned treatment options analyzed in this study
can vary with combination usage.
• Participants falling into different treatment options were
analyzed independently to see which treatment of pediatric
neuroblastoma is the most successful with the least amount of
adverse effects.
• When comparing different forms of treatment that may be
considered to treat pediatric neuroblastoma, studies and review
of different forms of treatments and their implication have been
conducted to determine what may be best for the patient, not
only during treatment, but in later years as well.

Pediatric Neuroblastoma - Conditions and Treatments, 2020).

Results

Introduction
• Previous research has discussed the effects of different

treatment options, including chemotherapy, radiation,
medication, and surgical treatment; however, no studies
have comprehensively compared different treatment
options in terms of treatment-related health
complications and success rates
• Many studies do not compare the lifelong effects that
each different treatment option has, which can aid in
determining which treatment option is best suited for
patient survival and patient quality of life both shortterm and long-term
• Research is needed to determine if there is a way to
treat pediatric neuroblastoma that will not affect the
child negatively both short-term and long-term.

Purpose
The current research seeks to review the existing
literature on available treatment options for pediatric
neuroblastoma (chemotherapy, radiation, medication
treatment, and surgical intervention) and to determine
which treatment option or combination of options would
be best for treating this devastating pediatric cancer. Adverse
effects of each type of treatment option are also
considered.

• Radiation
• Usage of radiographic endpoints were measured using
clinical metrics of renal function, creatinine and blood
urea nitrogen (BUN) values. An absolute increase was
observed for all patients in serum creatinine and blood urea
nitrogen was 0.07 mg/dL and 4.99 mg/dL, respectively
(Beckham et al., 2017).
• Surgical Procedures
• Patients who underwent surgical intervention had a higher
overall survival than those who had a biopsy only. There
was limited improvement when looking at the estimated
survival rates following any surgical intervention (Du et al.
2014). A statistically significant increase in survival
through the use of the primary tumor (P=0.02).
Unfortunately, surgical intervention was associated with
short-term advantage at the 2-year ES of 28.7%.
• Medication
• The prodrug-loaded nonoparticles (NP) caused a rapid
regression of large tumors and significantly delayed tumor
regrowth after cessation. The formulation strategy of the
NP enabled by a reversible chemical modification of drug
molecule achieved intratumoral drug levels, which
contributed to both potency and extended duration of
antitumor activity (Alferiev et al. 2015).
• Chemotherapy
• The overall survival rate was 96% (+/- 1%), with 98% of
patients who had favorable biologic features having a 3year survival, and 93% with unfavorable biologic features
present in the tumor (Baker et al., 2020).

Recommendations
• Radiation therapy should be used after diagnosis due to how long of
a process this treatment option takes to stop the spread and
progression of cancer
• Surgical treatment should be used for early to mid-stages of
detection and diagnosis of neuroblastoma.
• When tumors are small and have yet to spread and entangle to
structures and blood vessels, they are much simpler to surgically
resect as opposed to when cancerous tumors spread throughout the
brain and body, making it much more difficult to surgically resect.
• If neuroblastoma is diagnosed and detected in mid to late stages, and
or aggressive spread of cancer throughout the body is occurring,
chemotherapy should be used, it is often saved for when rapid
progression and spread for the disease has occurred due to patient’s
quality of life significantly worsening, as well as the many adverse
side effects that come with it.
• Chemotherapy yields best results in combination to radiation
therapy; this is because chemotherapy help weaken the spread and
progression of cancer cells which helps radiation work better in
eradicating them.
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